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ABSTRACT
Gap junctions and sodium channels are the major molecular determinants of 
normal and abnormal electrical conduction through the myocardium, however, their 
exact contributions to arrhythmogenesis are unclear. We examined conduction and 
recovery properties of regular (S1) and extrasystolic (S2) action potentials (APs), 
S1S2 restitution and ventricular arrhythmogenicity using the gap junction and sodium 
channel inhibitor heptanol (2 mM) in Langendorff-perfused mouse hearts (n=10). 
Monophasic action potential recordings obtained during S1S2 pacing showed that 
heptanol increased the proportion of hearts showing inducible ventricular tachycardia 
(0/10 vs. 5/8 hearts (Fisher’s exact test, P < 0.05), prolonged activation latencies 
of S1 and S2 APs, thereby decreasing S2/S1 activation latency ratio (ANOVA, P < 
0.05) despite prolonged ventricular effective refractory period (VERP). It did not 
alter S1 action potential duration at 90% repolarization (APD90) but prolonged S2 
APD90 (P < 0.05), thereby increasing S2/S1 APD90 ratio (P < 0.05). It did not alter 
maximum conduction velocity (CV) restitution gradient or maximum CV reductions 
but decreased the restitution time constant (P < 0.05). It increased maximal APD90 
restitution gradient (P < 0.05) without altering critical diastolic interval or maximum 
APD90 reductions. Pro-arrhythmic effects of 2 mM heptanol are explicable by delayed 
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conduction and abnormal electrical restitution. We concluded that gap junctions 
modulated via heptanol (0.05 mM) increased arrhythmogenicity through a delay in 
conduction, while sodium channel inhibition by a higher concentration of heptanol (2 
mM) increased arrhythmogenicity via additional mechanisms, such as abnormalities 
in APDs and CV restitution.
INTRODUCTION
Gap junctions and sodium channels are the 
major molecular determinants of conduction velocity 
(CV) of action potentials (APs) travelling through the 
myocardium [1–4]. Heptanol is a pharmacological 
agent that uncouples gap junctions at concentrations 
< 2 mM and additionally inhibits sodium channels > 2 
mM [5]. A number of investigators have examined the 
effects of this agent on ventricular arrhythmogenicity, 
demonstrating different effects in various model systems 
[6–9]. The reasons are likely attributable to distinct 
electrophysiological mechanisms observed in different 
animal models, pathophysiological conditions and 
drug concentrations used. For example, Callans and his 
colleagues demonstrated in a canine myocardial infarction 
model, that heptanol had a bimodal effect on ventricular 
arrhythmogenicity, with 0.5 mM heptanol increasing, 
and 1 mM heptanol decreasing, the incidence of induced 
VT [6]. In rabbit preparations, 1 mM heptanol reduced 
CV, increased the excitable gap and to a lesser extent the 
effective refractory period (ERP) as well as prolonged the 
cycle length during ventricular tachycardia [7].
By contrast, experiments from our group 
demonstrated ventricular pro-arrhythmic effects of 
heptanol at both 0.05 and 2 mM in Langendorff-perfused 
mouse hearts [9]. We showed that heptanol at 0.05 mM 
reduced CV without altering ERP or action potential 
duration (APD), leading to a reduction in excitation 
wavelength (λ = CV x ERP). At a higher concentration of 2 
mM, in addition to decreased CV, ERP was also increased, 
but this also led to a decrease in λ. However, none of 
the experiments described above explicitly examined 
the contributions of the conduction or repolarization 
properties of the extrasystolic APs that serve to initiate 
ventricular arrhythmias, nor did they examine restitution 
properties thought to be important in the generation of 
local tissue electrophysiological heterogeneities.
Firstly, conduction abnormalities of extrasystolic 
APs can increase arrhythmia inducibility [10]. Secondly, 
altered gap junction or sodium function can influence 
electrical restitution [11], potentially initiating APD 
alternans through steep APD restitution [12]. Alternans 
that are spatially discordant are thought to be more 
arrhythmogenic than those that are concordant. Spatially 
concordant can be converted to discordant APD alternans 
by mechanisms such as abnormal CV restitution [13–16].
In this study, therefore, we tested the hypotheses 
that i) an increased ratio of the activation latency of the 
extrasystolic AP to that of the regular AP, reflecting slower 
CV, and ii) altered ratio of APD of the extrasystolic AP to that 
of the regular AP and iii) abnormal CV or APD restitution 
contribute to the heptanol-induced arrhythmogenesis.
RESULTS
Ventricular arrhythmogenicity and its relationship 
to action potential activation and recovery properties of 
the regular and extrasystolic action potentials (APs) were 
examined before and after introduction of 0.05 or 2 mM 
heptanol in Langendorff-perfused mouse hearts. The right 
ventricular epicardium was electrically stimulated using a 
regular 8 Hz or S1S2 pacing protocol. Monophasic action 
potential (MAP) waveforms were recorded from the left 
ventricular epicardium. Ventricular tachycardia (VT) was 
defined as a series of five or more action potentials with 
coupling intervals closer than the basic cycle length (BCL).
Arrhythmogenicity studies and 
electrophysiological properties of S1 and S2 
action potentials in the presence or absence of 
heptanol during S1S2 pacing
The initial experiments confirmed previous findings 
that heptanol at both 0.05 and 2 mM exerted ventricular 
pro-arrhythmic effects, as demonstrated by the presence 
of inducible VT during the S1S2 protocol (Figure 1A 
to 1C). Under control conditions, 10 out of 10 hearts 
reached refractory outcomes during programmed electrical 
stimulation. In the presence of 0.05 mM heptanol, this 
proportion was increased to 5 out of 10 hearts. At a 
higher concentration of 2 mM heptanol, 5 out of 8 hearts 
showed evidence of inducible VT. Therefore, heptanol at 
both concentrations exerted significant arrhythmogenic 
effects compared with control (Figure 2; Fisher’s Exact 
Test, P < 0.05). The S2 activation latency increased 
(Figure 3A to 3C) with progressive shortening in the S1S2 
interval both before and after introduction of 0.05 or 2 
mM heptanol. Similarly, the S2 action potential duration 
(APD at 90% repolarization, APD90) decreased with a 
progressive shortening in the S1S2 interval under these 
pharmacological conditions (Figure 4A to 4C).
Activation latency of the regular (S1) action potential 
(AP) was increased from 12.0 ± 0.4 to 19.7 ± 1.8 ms by 
0.05 mM heptanol (n = 10), and increased further to 26.5 
± 2.4 ms by 2 mM heptanol (n = 8) (Figure 5A; P < 0.05). 
Similarly, activation latency of the extrasystolic (S2) AP 
was increased from 24.7 ± 2.2 to 33.9 ± 2.6 ms by 0.05 mM 
heptanol (n = 10), and further increased to 39.6 ± 4.0 ms by 
2 mM heptanol (n = 8) (Figure 5B; P < 0.05). Consequently, 
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Figure 1: No ventricular arrhythmias were observed before introduction of heptanol (A), in contrast to inducible ventricular tachycardia 
(VT) occurring after 0.05 mM (B) or 2 mM (C) heptanol treatment during S1S2 pacing.
Figure 2: Incidence of inducible ventricular tachycardia (VT) under control conditions and in the presence of 0.05 mM 
or 2 mM heptanol.
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the S2 to S1 activation latency ratio was decreased from 2.1 
± 0.3 to 1.8 ± 0.1 by 0.05 mM heptanol (n = 10), and further 
to 1.5 ± 0.1 ms by 2 mM heptanol (n = 8) (Figure 5C).
APD90 of the S1 AP was not significantly altered by 
0.05 mM or 2 mM heptanol (Figure 6A; 41.6 ± 1.9 vs 39.5 
± 2.7 vs 43.3 ± 0.8 ms; P > 0.05). Whilst APD90 of the S2 
AP was similarly unaltered by 0.05 mM heptanol (n = 10) 
(Figure 6B; 31.1 ± 2.2 vs. 33.3 ± 1.7; P > 0.05), it was 
prolonged by 2 mM heptanol to 39.1 ± 1.0 (n = 8) (P < 
0.05). The S2 to S1 APD90 ratio was consequently unaltered 
by 0.05 mM heptanol (n = 10) (Figure 6C; 0.75 ± 0.04 vs. 
0.86 ± 0.05; P > 0.05), but reduced by 2 mM heptanol to 
0.90 ± 0.01 (n = 8) (P < 0.05). VERP was not altered by 
0.05 mM heptanol (n = 10) (42.0 ± 4.5 ms vs. 42.2 ± 3.0 
ms; P > 0.05) but was increased by 2 mM heptanol (n = 8) 
(Figure 7; 56.3 ± 5.9 ms; P < 0.05).
APD90 and CV restitution properties determined 
from S1S2 pacing in the presence or absence of 
heptanol
Figures 8A to 8C show examples of conduction 
velocity (CV) restitution curves (solid lines, left ordinates) 
and their gradients (broken lines, right axes) under the same 
pharmacological conditions described above, with fitted 
parameters summarized in Table 1. Maximum CV restitution 
gradients (Figure 8D) or maximum CV reduction (Figure 
8F) was not altered by 0.05 (n = 10) or 2 mM heptanol (n 
= 8). By contrast, the time constants τ of the restitution 
curves was unaltered by 0.05 mM heptanol (n = 10) but was 
decreased by 2 mM heptanol (n = 8) (Figure 8E).
Figure 9A to 9C shows examples of APD90 
restitution curves (solid lines, left ordinates) and their 
gradients (broken lines, right axes) before or after 
introduction of 0.05 (n = 10) or 2 mM heptanol (n = 8); 
fitted parameters are summarized in Table 2. Maximal 
APD90 restitution gradients was not altered by 0.05 mM 
heptanol (n = 10) but was increased by 2 mM heptanol (n 
= 8) (Figure 9D). By contrast, both DIcrit (Figure 9E) and 
maximum APD90 reductions (Figure 9F) was unaltered by 
0.05 (n = 10) or 2 mM heptanol (n = 8) (P < 0.05).
DISCUSSION
Extrasystolic action potentials can initiate 
ventricular tachy-arrhythmias, which can be sustained 
Figure 3: S2 activation latency plotted against S1S2 interval before (A) and after introduction of 0.05 mM (B) or 2 mM (C) heptanol from 
a representative heart.
Figure 4: S2 APD90 plotted against S1S2 interval before (A) and after introduction of 0.05 mM (B) or 2 mM (C) heptanol.
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in the presence of favourable re-entrant substrates 
such as areas of abnormal conduction [17–19]. A key 
determinant of cardiac conduction is gap junctions [20–
22], whose roles in ventricular arrhythmogenesis have 
been extensively studied in different animal systems [23] 
such as canine myocardial infraction model [24] and rabbit 
heart failure model [25]. These models are excellent for 
characterization of long-term electrophysiological and 
structural remodeling of the myocardium.
Of the different animal models, mouse hearts 
have been a popular system for investigating cardiac 
electrophysiology owing to their ease of reproduction, 
access, genetic and pharmacological manipulation [26, 
27]. For example, the effects of loss of the gap junction 
protein, connexin 43, have been studied in great detail 
[13, 22, 28–36]. Genetic modification has been achieved 
by cardiac-restricted inactivation of Cx43 and subsequent 
crossing with Cre recombinase produced mice with 
mosaicism [28]. In this model, Cx43 levels were reduced 
by 86 to 95%. Moreover, in heterozygous Cx43+/- mice, 
Cx43 expression was decreased by 45 to 50%. CV was 
unaffected [13, 22, 30, 31, 34, 35] or decreased up to 44% 
in these models [29, 32, 33].
In addition to these genetic models, pharmacological 
studies have tested the acute effects of altered gap 
junction function using uncouplers such as carbenoxolone 
[37], palmitoleic acid [38] or heptanol [6, 7] have 
been used. Of these agents, heptanol uncouples at 
concentrations < 2 mM and additionally inhibits sodium 
channels when applied at concentrations > 2 mM [5, 
Figure 5: S1 activation latencies (A) and S2 activation latencies (B) immediately before reaching a refractory or an arrhythmic outcome, 
and S2 latency / S1 latency ratio before and after introduction of 0.05 mM or 2 mM heptanol (C).
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39, 40]. In infarcted canine hearts, heptanol had a dual 
effect on ventricular arrhythmogenicity, increasing 
ventricular arrhythmogenicity at 0.5 mM but decreasing 
arrhythmogenicity at 1 mM [6]. By contrast, in mouse 
hearts, pro-arrhythmic effects have been observed across 
the concentrations from 0.05 mM to 2 mM [9, 41].
Thus, in the presence of 0.05 mM heptanol, an 
increase in the incidence of inducible, but not spontaneous, 
ventricular tachycardia (VT) was observed, which was 
associated with increases in activation latencies, which 
reflect reduced conduction velocity or alterations of 
the conduction pathway, in an absence of alterations 
in action potential durations (APDs) or ventricular 
effective refractory periods (VERPs) [9]. By contrast, at 
a higher concentration of 2 mM, both the incidences of 
spontaneous and inducible VT were increased [41]. These 
arrhythmogenic phenomena were associated with further 
increases in activation latency and VERP. Therefore, 
heptanol at 2 mM, but not 0.05 mM, induced post-
repolarization refractoriness, which is expected to inhibit, 
rather than induce, ventricular arrhythmogenesis.
However, in these previous studies, neither 
the behaviour of hearts once these extrasystolic APs 
were initiated, nor abnormal electrical restitution, was 
investigated. Therefore, the present study examined the 
effects of heptanol on conduction slowing and abnormal 
repolarization of extrasystolic APs as well as abnormal 
electrical restitution, and their relationships with 
ventricular arrhythmogenicity. Our initial experiments first 
confirmed the pro-arrhythmic effects of heptanol at both 
Figure 6: S1 APD (A) and S2 APD (B) immediately before reaching a refractory or an arrhythmic outcome and S2 APD90 / S1 APD90 ratio 
before and after introduction of 0.05 mM or 2 mM heptanol (C).
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0.05 and 2 mM using programmed electrical stimulation 
that delivered increasingly premature extrasystolic, S2 
pacing stimuli following trains of regular S1 stimuli. 
Heptanol increased the activation latency of both the S1 
and S2 APs. However, it produced a decrease, rather than 
increase, in the S2 to S1 activation latency ratio. In other 
words, there was a smaller degree of conduction slowing 
or change in conduction pathway of extrasystolic APs 
relative to the regular APs in the presence of heptanol. 
Therefore, the arrhythmogenesis observed was not 
explicable by conduction defects of the extrasystolic APs. 
Moreover, previous experiments found that arrhythmic 
outcomes were associated with lower CVs in their 
initiating extrasystolic APs than refractory outcomes in a 
long QT syndrome mouse model [10]. However, activation 
latencies in the arrhythmic and refractory groups were not 
significantly different from each other in our model.
Moreover, previous reports have associated 
increased arrhythmogenicity with increases in maximum 
APD90 restitution gradients, critical diastolic intervals 
(DIs, DIcrit), and APD90 heterogeneity in a pharmacological 
mouse model of long QT syndrome [42, 43]. Increased 
arrhythmogenicity in other model systems has been 
associated with abnormal activation latency restitution 
Figure 7: Ventricular effective refractory period (VERP) before and after introduction of 0.05 mM or 2 mM heptanol.
Figure 8: Restitution curves plotting CV against preceding DI obtained before (A) and after introduction of 0.05 (B) or 2 mM heptanol 
(C). Curves were fitted with mono-exponential growth functions obtained by least-squares fitting to the values of CV and DI (solid lines, 
left ordinates). Gradients were obtained by differentiation of the fitted functions (broken lines, right axes). Maximum CV restitution 
gradients (D), time constants of restitution curves (E) and maximum CV reductions (F).
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properties. The latter is observed as increased maximum 
restitution gradients [14], increased time constants of the 
restitution curves [15, 44] and increased heterogeneity in 
activating latency, given by maximal increase between 
the longest and shortest S1S2 intervals studied was 
seen in D600-treated rabbit hearts [12]. Restitution 
analysis of data obtained during PES revealed a steeper 
APD restitution and a shorter time constant for the CV 
restitution curve in the presence of 2 mM heptanol. At a 
lower concentration of 0.05 mM, all of the APD and CV 
restitution parameters remained unaltered.
Limitations
There are several limitations of this study, which are 
mainly due to the experimental methodology used. Firstly, 
it was not possible to determine the exact conduction 
velocities (CVs) as single point measurements were 
made from the hearts. Altered activation latencies in this 
study could well be attributed to alterations in conduction 
path of the propagating action potentials in addition to 
reduced conduction velocity. A better method would be 
the use of optical mapping, which can determine CVs 
from multi-point recordings, and distinguish reduced CVs 
from alterations in conduction path as well as orientation 
of myocardial fibres. Secondly, higher concentrations 
of heptanol (2 mM in this study) have dual effects on 
activation and repolarization. Therefore, it was not 
possible to elucidate what selective sodium channel block, 
gap junctional block or repolarization heterogeneity plays 
in heptanol-induced arrhythmogenesis. Future studies 
using selective gap junction blockers and openers would 
provide additional insight.
CONCLUSIONS
In conclusion, our data suggest that gap 
junctions modulated via heptanol (0.05 mM) increased 
arrhythmogenicity through a delay in conduction, while 
sodium channel inhibition by a higher concentration 
Figure 9: Restitution curves plotting APD90 against preceding diastolic interval (DI) before (A) and after introduction of 0.05 (B) 
or 2 mM heptanol (C). Curves were fitted with mono-exponential growth functions obtained by least-squares fitting to the values of APD90 
and DI (solid lines, left ordinates). Gradients were obtained by differentiation of the fitted functions (broken lines, right axes). Maximum 
APD90 restitution gradients (D), critical diastolic intervals (E) and maximum APD90 reductions (F).
Table 1: Fitted parameters for CV restitution curves
Condition yo (m/s) A (m/s) τ (s)
control 0.216 ± 0.013 -0.255 ± 0.092 0.0129 ± 0.003
0.05 mM heptanol 0.180 ± 0.012 -1.350 ± 1.215 0.0124 ± 0.003
2 mM heptanol 0.134 ± 0.008 -0.102 ± 0.027 0.0044 ± 0.001
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of heptanol (2 mM) increased arrhythmogenicity by 




Krebs-Henseleit solution (composition in mM: NaCl 
119, NaHCO3 25, KCl 4, KH2PO4 1.2, MgCl2 1, CaCl2 
1.8, glucose 10 and sodium pyruvate 2, pH 7.4), which 
has been bicarbonate-buffered and bubbled with 95% 
O2–5% CO2, was used in the experiments described in this 
study. Heptanol (Sigma, Dorset, UK; density: 0.82 g ml) 
is an agent that remains soluble in aqueous solutions up 
to 9 mM (The Merck Index, New Jersey, USA). Krebs-
Henseleit solution was used to dilute the heptanol solution 
to produce a final concentration of 0.05 and 2 mM.
Preparation of Langendorff-perfused mouse 
hearts
This study was approved by the Animal Welfare 
and Ethical Review Body at the University of Cambridge. 
Wild-type mice of 129 genetic background between 5 and 
7 months of age were used. They were maintained at room 
temperature (21 ± 1°C) and were subjected to a 12:12 h 
light / dark cycle with free access to sterile rodent chow 
and water in an animal facility. Mice were terminated 
by dislocation of the cervical spine in accordance with 
Sections 1(c) and 2 of Schedule 1 of the UK Animals 
(Scientific Procedures) Act 1986. After removal from 
their chest cavities, the hearts were submerged in ice-cold 
Krebs-Henseleit solution. The aortas were cannulated 
using a custom-made 21-gauge cannula prefilled with ice-
cold buffer. A micro-aneurysm clip (Harvard Apparatus, 
UK) was used to secure the hearts onto the Langendorff 
perfusion system. Retrograde perfusion was carried out 
at a flow rate of 2 to 2.5 ml min-1 by use of a peristaltic 
pump (Watson–Marlow Bredel pumps model 505S, 
Falmouth, Cornwall, UK). The perfusate passed through 
successively 200 and 5 μm filters and warmed to 37°C 
using a water jacket and circulator before arriving at the 
aorta. Approximately 90% of the hearts regained their 
pink colour and spontaneous rhythmic activity. These 
were therefore studied further. The remaining 10% did not 
and were discarded. The hearts were perfused for a further 
20 minutes to minimise residual effects of endogenous 
catecholamine release, before their electrophysiology 
properties were characterized.
Stimulation protocols
Paired platinum electrodes (1 mm interpole 
distance) were used to stimulate the right ventricular 
epicardium electrically. This took place at 8 Hz, using 
square wave pulses of 2 ms in duration, with a stimulation 
voltage set to thrice the diastolic threshold (Grass S48 
Stimulator, Grass-Telefactor, Slough, UK) immediately 
after the start of perfusion. The S1S2 protocol was used 
to assess arrhythmogenicity and identify re-entrant 
substrates. This consisted of a drive train of eight regularly 
paced S1 stimuli separated by a 125 ms basic cycle length 
(BCL), followed by premature S2 extra-stimuli every 
ninth stimulus. The S1S2 interval was first set to 125 ms 
and then successively reduced by 1 ms with each nine 
stimulus cycle until arrhythmic activity was initiated or 
refractoriness was reached, whereupon the S2 stimulus 
elicited no ventricular response.
Recording procedures
A Monophasic action potential (MAP) electrode 
was used to record MAPs from the left ventricular 
epicardium (Linton Instruments, Harvard Apparatus). The 
stimulating and recording electrodes were maintained at 
constant positions separated approximately by distance 
of 3 mm. This means the inverse of the activation 
latencies is proportional to the conduction velocity 
(CV). All recordings were performed using a baseline 
cycle length (BCL) of 125 ms (8 Hz) to exclude rate-
dependent differences in action potential durations 
(APDs). MAPs were pre-amplified using a NL100AK 
head stage, amplified with a NL 104A amplifier and 
band pass filtered between 0.5 Hz and 1 kHz using a 
NL125/6 filter (Neurolog, Hertfordshire, UK) and then 
digitized (1401plus MKII, Cambridge Electronic Design, 
Cambridge, UK) at 5 kHz. Waveforms were analysed 
using Spike2 software (Cambridge Electronic Design, 
UK). MAP waveforms that did not match established 
criteria for MAP signals were rejected [45, 46]. They 
must have “stable baselines, fast upstrokes, with no 
Table 2: Fitted parameters for APD restitution curves
Condition yo (s) A (s) τ (s)
control 0.039 ± 0.002 -0.045 ± 0.010 0.011 ± 0.001
0.05 mM heptanol 0.043 ± 0.002 -0.038 ± 0.002 0.012 ± 0.001
2 mM heptanol 0.051 ± 0.002 -0.068 ± 0.017 0.004 ± 0.001
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inflections or negative spikes, and a rapid first phase of 
repolarization”. 0% repolarization was measured at the 
peak of the MAP and 100% repolarization was measured 
at the point of return of the potential to baseline [45, 47, 
48].
The following parameters were obtained from the 
experimental records: (1) Activation latency, defined as 
the time difference between the stimulus and the peak 
of the MAP, of the action potentials obtained follow S1 
and S2 stimulation at different S1S2 intervals; (2) APDx, 
the time difference between the peak of the MAP and 
x = 30, 50, 70 and 90% repolarization of the S1 APs 
and S2 APs at different S1S2 intervals; (3) restitution 
gradient obtained from restitution curves plotting 
conduction velocity (CV, inter-electrode distance / 
activation latency) against the previous DI, assuming its 
maximal value at the shortest S1S2 interval studied; (4) 
CV restitution curve time constant, τ; (5) Maximum CV 
reduction, a measure of restitution heterogeneity, defined 
as the maximum change in CV observed between the 
longest and shortest S1S2 interval achieved during PES 
[12, 49]; (6) APD90 restitution gradient obtained from 
restitution curves plotting APD90 against the previous 
diastolic interval (DI), assuming a maximum gradient at 
the shortest S1S2 interval studied; (7) Critical DI, DIcrit, 
defined as the DI at which the gradient of the APD90 
restitution curve reaches unity; (8) Maximum APD90 
reduction, a measure of APD90 restitution heterogeneity, 
defined as the maximum APD90 reduction observed 
between the longest and shortest S1S2 intervals achieved 
during PES [12, 50];
In this study, restitution curves were constructed 
using the PES data obtained above, by plotting activation 
latency or APD90 against the preceding DI, and were 
then fitted with an exponential function of the form 
y y Ae x= + −
0
/τ  by a least-squares method using a 
Levenberg-Marquardt algorithm. y represents either 
APD90 or CV, and x represents DI, whereas y0, A and τ 
are constants. The gradient is given by 
dy
dx
A e x= −
τ
τ/ , 
assuming its maximal value at the shortest S1S2 interval 
reached during PES. DIcrit was defined as the DI at which 
the gradient of the fitted function reached unity. Maximum 
CV or maximum APD90 reduction, reflecting heterogeneity 
in restitution, was defined as the difference between values 
obtained at the longest S1S2 interval and those obtained at 
the shortest S1S2 interval.
Statistical analysis
All values were expressed as mean ± standard error 
of the mean (SEM). Categorical data were compared 
with Fisher's exact test (two-tailed). Numerical data were 
compared by one-way analysis of variance (ANOVA). P 
< 0.05 was considered statistically significant and was 
denoted by * in the figures.
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